- Investor's Business Daily•8 minutes ago
Neurocrine's Tourette drug failed in a trial and the FDA approved a generic narcolepsy drug rivaling Jazz, and both stocks fell late.
- TheStreet.com•1 hour ago
The same Neurocrine drug, valbenazine, is currently under review at the FDA as a treatment for the movement disorder tardive dyskinesia.
- PR Newswire•2 hours agoNeurocrine Announces Completion of Phase II Clinical Study of VMAT2 Inhibitor INGREZZA™ (valbenazine) in Adults with Tourette Syndrome
While the study showed a significant improvement in overall symptoms of Tourette syndrome as evidenced by the Clinical Global Impression of Change (p=0.015), the pre-specified primary endpoint, the change-from-baseline in the Yale Global Tic Severity Scale (YGTSS) at Week 8 was not met (p=0.18). Adverse events were dose dependent and consistent with earlier clinical studies. "Overall we were very pleased with the conduct of the study, including the investigators' administration of the Yale Global Tic Severity Scale as well as the safety profile of INGREZZA in adults with Tourette syndrome," said Chris O'Brien, Chief Medical Officer of Neurocrine.
NBIX : Summary for Neurocrine Biosciences, Inc. - Yahoo Finance
Neurocrine Biosciences, Inc. (NBIX)
NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
|Bid||38.30 x 800|
|Ask||38.90 x 100|
|Day's Range||39.87 - 42.28|
|52 Week Range||31.25 - 55.15|
Trade prices are not sourced from all markets
|PE Ratio (TTM)||-27.65|
|Dividend & Yield||0.00 (0.00%)|
|1y Target Est||N/A|